Skip to main content
Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases 11/2007

01.11.2007 | Article

Necrotizing fasciitis caused by Vibrio vulnificus: epidemiology, clinical findings, treatment and prevention

verfasst von: Y.-L. Kuo, S.-J. Shieh, H.-Y. Chiu, J.-W. Lee

Erschienen in: European Journal of Clinical Microbiology & Infectious Diseases | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

Necrotizing fasciitis is a soft-tissue infection with a high risk of fatality. Infection with Vibrio vulnificus can lead to development of necrotizing fasciitis and primary septicemia, and occurs mostly in immunocompromised host-associated diseases such as hepatic disease, diabetes mellitus, chronic renal insufficiency, and adrenal insufficiency. Early recognition and treatment of the infection, which are unclear, are vital to patient welfare. We studied the disease epidemiology and reviewed the prognosis and clinical features of patients treated using our developed protocol. Clinical manifestations and outcomes were retrospectively analyzed for 67 patients with V. vulnificus-mediated necrotizing fasciitis and sepsis. All patients who had contacted seawater or raw seafood with positive culture for vibrio were included. Patients were divided into two groups based on the timing of first fasciotomy and injury; within 24 h (group A) and beyond 24 h (group B). Twenty-three of the 67 patients (40%) had hepatic disease, 17 (25.4%) had chronic renal insufficiency, and 12 (17.9%) exhibited adrenal insufficiency. The most common site of infection was the upper extremity (74.7%). Group B presented with more clinical symptoms including fever (p = 0.02), hemorrhagic bullae (p < 0.0001), and shock (p = 0.007). Group A patients exhibited enhanced survival compared to group B (in hospital mortality: 4.9% vs. 23%; p = 0.005). We conclude that early and appropriate diagnosis for V. vulnificus infection should be made, especially in patients presenting with atypical clinical findings. Early fasciotomy within 24 h remains the highest priority and decreases the mortality rate.
Literatur
1.
Zurück zum Zitat Blake PA, Merson MH, Weaver RE et al (1979) Disease caused by a marine Vibrio: clinical characteristics and epidermiology. N Engl J Med Jan 4;300(1):1–5 Blake PA, Merson MH, Weaver RE et al (1979) Disease caused by a marine Vibrio: clinical characteristics and epidermiology. N Engl J Med Jan 4;300(1):1–5
2.
Zurück zum Zitat Neil MA, Carpenter CCJ (2000) Vibrio vulnificus infection. In: Mandell GL, Bennet JE, Dolin R (eds) Principles and practice of infectious diseases, 5th edn. Livingston, Edinburgh, Scotland, pp 2274 Neil MA, Carpenter CCJ (2000) Vibrio vulnificus infection. In: Mandell GL, Bennet JE, Dolin R (eds) Principles and practice of infectious diseases, 5th edn. Livingston, Edinburgh, Scotland, pp 2274
4.
Zurück zum Zitat Oliver JD (2005) Wound infection caused by Vibrio vulnificus and other marine bacteria. Epidermiol Infect 133:383–391CrossRef Oliver JD (2005) Wound infection caused by Vibrio vulnificus and other marine bacteria. Epidermiol Infect 133:383–391CrossRef
5.
Zurück zum Zitat Hsueh PR, Lin CY, Tang HJ et al (2004) Vibrio vulnificus in Taiwan. Emerg Infect Dis 8:1363–1368 Hsueh PR, Lin CY, Tang HJ et al (2004) Vibrio vulnificus in Taiwan. Emerg Infect Dis 8:1363–1368
6.
Zurück zum Zitat Hor LI, Chang TT, Wang ST (1999) Survival of Vibrio vulnificus in whole blood from patients with chronic liver diseases: association with phagocytosis by neutrophils and serum ferritin levels. J Infec Dis 179:275–278CrossRef Hor LI, Chang TT, Wang ST (1999) Survival of Vibrio vulnificus in whole blood from patients with chronic liver diseases: association with phagocytosis by neutrophils and serum ferritin levels. J Infec Dis 179:275–278CrossRef
7.
Zurück zum Zitat Bullen JJ, Spalding PB, Ward CG et al (1991) Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch Intern Med 151:1606–1609PubMedCrossRef Bullen JJ, Spalding PB, Ward CG et al (1991) Hemochromatosis, iron and septicemia caused by Vibrio vulnificus. Arch Intern Med 151:1606–1609PubMedCrossRef
8.
Zurück zum Zitat Katz BZ (1988) Vibrio vulnificus meningitis in a boy with thalassemia after eating raw oysters. Pediatrics 82:784–786PubMed Katz BZ (1988) Vibrio vulnificus meningitis in a boy with thalassemia after eating raw oysters. Pediatrics 82:784–786PubMed
9.
Zurück zum Zitat Kihiczak GG, Schwartz RA, Kapila R (2006) Necrotizing fasciitis: a deadly infection. J Eur Acad Dermatol Venereol 20:365–369PubMedCrossRef Kihiczak GG, Schwartz RA, Kapila R (2006) Necrotizing fasciitis: a deadly infection. J Eur Acad Dermatol Venereol 20:365–369PubMedCrossRef
10.
Zurück zum Zitat Baethge BA, West BC (1988) Vibrio vulnificus: did Hippocrates describe a fatal case? Rev Infect Dis 10:614–615PubMed Baethge BA, West BC (1988) Vibrio vulnificus: did Hippocrates describe a fatal case? Rev Infect Dis 10:614–615PubMed
11.
Zurück zum Zitat Yuan CY, Yuan CC, Wei DC et al (1987) Septicemia and gangrenous change of the leg caused by marine vibrio, Vibrio vulnificus: report of a case. J Formos Med Assoc 86:448–451 Yuan CY, Yuan CC, Wei DC et al (1987) Septicemia and gangrenous change of the leg caused by marine vibrio, Vibrio vulnificus: report of a case. J Formos Med Assoc 86:448–451
12.
Zurück zum Zitat Wang SM, Liu CC, Chiou YY et al (2000) Vivrio vulnificus infection complicated by acute respiratory distress syndrome in a child with nephritic syndrome. Pediatr Pulmonol 29:400–403PubMedCrossRef Wang SM, Liu CC, Chiou YY et al (2000) Vivrio vulnificus infection complicated by acute respiratory distress syndrome in a child with nephritic syndrome. Pediatr Pulmonol 29:400–403PubMedCrossRef
13.
Zurück zum Zitat Tsai YH, Hsu WW, Huang KC et al (2004) Systemic vibrio infection presenting as necrotizing fasciitis and sepsis: a series of thirteen cases. J Bone Joint Surg. Am 86:2497–2502PubMed Tsai YH, Hsu WW, Huang KC et al (2004) Systemic vibrio infection presenting as necrotizing fasciitis and sepsis: a series of thirteen cases. J Bone Joint Surg. Am 86:2497–2502PubMed
14.
Zurück zum Zitat Jaenisch T, Patz J (2002) Assessment of associations between climate and infectious diseases. Global Change Human Health 3(1):67–72CrossRef Jaenisch T, Patz J (2002) Assessment of associations between climate and infectious diseases. Global Change Human Health 3(1):67–72CrossRef
15.
Zurück zum Zitat Paz S, Bisharat N, Paz E et al (2007) Climate change and the emergence of Vibrio vulnificus disease in Israel. Environ Res 103:390–396PubMedCrossRef Paz S, Bisharat N, Paz E et al (2007) Climate change and the emergence of Vibrio vulnificus disease in Israel. Environ Res 103:390–396PubMedCrossRef
16.
Zurück zum Zitat Chuang YC, Ko WC, Wang ST et al (1998) Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother 42(6):1319–1322PubMed Chuang YC, Ko WC, Wang ST et al (1998) Minocycline and cefotaxime in the treatment of experimental murine Vibrio vulnificus infection. Antimicrob Agents Chemother 42(6):1319–1322PubMed
17.
Zurück zum Zitat Liu YC, Shyu TG, Suen TT (1989) Investigation of the adulteration of synthetic chemical drugs in marketed Chinese herbal rheumatic and analgesic preparations. Annual Report of the National Laboratories of Foods and Drugs, vol 7. Department of Health, Taipei, Taiwan, pp 197–199 Liu YC, Shyu TG, Suen TT (1989) Investigation of the adulteration of synthetic chemical drugs in marketed Chinese herbal rheumatic and analgesic preparations. Annual Report of the National Laboratories of Foods and Drugs, vol 7. Department of Health, Taipei, Taiwan, pp 197–199
18.
Zurück zum Zitat Huang WF, Wen KC, Hsiao ML (1997) Adulteration by synthetic therapeutic substances of traditional Chinese medicine in Taiwan. J Clin Pharmacol 37:344–350PubMed Huang WF, Wen KC, Hsiao ML (1997) Adulteration by synthetic therapeutic substances of traditional Chinese medicine in Taiwan. J Clin Pharmacol 37:344–350PubMed
19.
Zurück zum Zitat Ernst E (2002) Adulteration of Chinese herbal medicines with synthetic drugs: a systemic review. J Inter Med 252:107–113CrossRef Ernst E (2002) Adulteration of Chinese herbal medicines with synthetic drugs: a systemic review. J Inter Med 252:107–113CrossRef
20.
Zurück zum Zitat Espat NJ, Auffenberg T, Abouhamze A et al (1996) A role for Tumor Necrosis Factor Alpha in the increased mortality associated with Vibrio vulnificus infection in the presence of hepatic dysfunction. Ann Surg 223(4):428–433PubMedCrossRef Espat NJ, Auffenberg T, Abouhamze A et al (1996) A role for Tumor Necrosis Factor Alpha in the increased mortality associated with Vibrio vulnificus infection in the presence of hepatic dysfunction. Ann Surg 223(4):428–433PubMedCrossRef
21.
Zurück zum Zitat Howard RJ, Lieb S (1988) Soft-tissue infections caused by halophilic marine vibrios. Arch Surg 123:245–249PubMed Howard RJ, Lieb S (1988) Soft-tissue infections caused by halophilic marine vibrios. Arch Surg 123:245–249PubMed
22.
Zurück zum Zitat Powell JL, Wright AC, Wasserman SS et al (1997) Release of Tumor Necrosis Factor Alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models. Infec Immun 65(9):3713–3718 Powell JL, Wright AC, Wasserman SS et al (1997) Release of Tumor Necrosis Factor Alpha in response to Vibrio vulnificus capsular polysaccharide in in vivo and in vitro models. Infec Immun 65(9):3713–3718
23.
Zurück zum Zitat Shin SH, Shin DH, Ryu PY et al (2002) Proinflammatory cytokine profile in Vibrio vulnificus septicemic patients’ sera. FEMS Immun Med Microb 33(2):133–138CrossRef Shin SH, Shin DH, Ryu PY et al (2002) Proinflammatory cytokine profile in Vibrio vulnificus septicemic patients’ sera. FEMS Immun Med Microb 33(2):133–138CrossRef
24.
Zurück zum Zitat Klontz KC, Lieb S, Schreiber M et al (1988) Syndromes of Vibrio vulnificus infections: clinical and epidemiological features in Florida case, 1981–1987. Ann Intern Med 109:318–323PubMed Klontz KC, Lieb S, Schreiber M et al (1988) Syndromes of Vibrio vulnificus infections: clinical and epidemiological features in Florida case, 1981–1987. Ann Intern Med 109:318–323PubMed
25.
Zurück zum Zitat Chuang YC, Yuan CY, Liu CY et al (1992) Vibrio vulnificus infection in Taiwan: report of 28 cases and review of clinical manifestations and treatment. Clin Infect Dis Aug 15:271–276 Chuang YC, Yuan CY, Liu CY et al (1992) Vibrio vulnificus infection in Taiwan: report of 28 cases and review of clinical manifestations and treatment. Clin Infect Dis Aug 15:271–276
26.
Zurück zum Zitat Yau BC, Lee JW, Chen CL et al (1995) Surgical treatment in vibrio infection. J Plast Reconst Surg ROC 4 1:21–27 Yau BC, Lee JW, Chen CL et al (1995) Surgical treatment in vibrio infection. J Plast Reconst Surg ROC 4 1:21–27
27.
Zurück zum Zitat Wong CH, Chang HC, Pasupathy S et al (2003) Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am Aug 85(8):1454–1460 Wong CH, Chang HC, Pasupathy S et al (2003) Necrotizing fasciitis: clinical presentation, microbiology, and determinants of mortality. J Bone Joint Surg Am Aug 85(8):1454–1460
28.
Zurück zum Zitat Halow KD, Harner RC, Fontenelle LJ (1996) Primary skin infection secondary to Vibrio vulnificus: the role of operative intervention. J Am Coll Surg 183:329–334PubMed Halow KD, Harner RC, Fontenelle LJ (1996) Primary skin infection secondary to Vibrio vulnificus: the role of operative intervention. J Am Coll Surg 183:329–334PubMed
29.
Zurück zum Zitat Chuang YC, Liu JW, Ko WC et al (1997) In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus. Antimicrob Agents Chemother 41(10):2214–2217PubMed Chuang YC, Liu JW, Ko WC et al (1997) In vitro synergism between cefotaxime and minocycline against Vibrio vulnificus. Antimicrob Agents Chemother 41(10):2214–2217PubMed
30.
Zurück zum Zitat Chiang SR, Chuang YC (2003) Vibrio vulnificus infection: clinical manifestation, pathogenesis, and antimicrobial therapy. J Microbiol Immunol Infect 36:81–88PubMed Chiang SR, Chuang YC (2003) Vibrio vulnificus infection: clinical manifestation, pathogenesis, and antimicrobial therapy. J Microbiol Immunol Infect 36:81–88PubMed
31.
Zurück zum Zitat Liu JW, Lee IK, Tang HJ et al (2006) Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med 166:2117–2123PubMedCrossRef Liu JW, Lee IK, Tang HJ et al (2006) Prognostic factors and antibiotics in Vibrio vulnificus septicemia. Arch Intern Med 166:2117–2123PubMedCrossRef
32.
Zurück zum Zitat Tang HJ, Chang MC, Ko WC et al (2002) In Vitro and In Vivo activities of newer fluoroquinolones against Vibrio vulnificus. Antim Agen Chem Nov:3580–3584 Tang HJ, Chang MC, Ko WC et al (2002) In Vitro and In Vivo activities of newer fluoroquinolones against Vibrio vulnificus. Antim Agen Chem Nov:3580–3584
33.
Zurück zum Zitat Elliott DC, Kufera JA, Myers RAM (1996) Necrotizing soft tissue infections: risk factors for mortality and strategies for management. Ann Surg 224(5):672–683PubMedCrossRef Elliott DC, Kufera JA, Myers RAM (1996) Necrotizing soft tissue infections: risk factors for mortality and strategies for management. Ann Surg 224(5):672–683PubMedCrossRef
34.
Zurück zum Zitat Childers BJ, Potyondy LD, Nachreiner R et al (2002) Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients. Am Surg Feb 68(2):109–116 Childers BJ, Potyondy LD, Nachreiner R et al (2002) Necrotizing fasciitis: a fourteen-year retrospective study of 163 consecutive patients. Am Surg Feb 68(2):109–116
Metadaten
Titel
Necrotizing fasciitis caused by Vibrio vulnificus: epidemiology, clinical findings, treatment and prevention
verfasst von
Y.-L. Kuo
S.-J. Shieh
H.-Y. Chiu
J.-W. Lee
Publikationsdatum
01.11.2007
Verlag
Springer-Verlag
Erschienen in
European Journal of Clinical Microbiology & Infectious Diseases / Ausgabe 11/2007
Print ISSN: 0934-9723
Elektronische ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-007-0358-5

Weitere Artikel der Ausgabe 11/2007

European Journal of Clinical Microbiology & Infectious Diseases 11/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.